Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug containing four active ingredients: aniracetam, dihydroergocristine, nimodipine, and piracetam. **Dihydroergocristine** is an ergot alkaloid that has partial agonist activity on dopaminergic and alpha-adrenergic receptors and antagonist activity on serotonin receptors. It is used in some countries for the treatment of cerebral and peripheral vascular events. **Nimodipine** is a calcium channel blocker that acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. It helps increase blood flow to the brain by dilating small blood vessels and is used to prevent brain damage caused by reduced blood flow following subarachnoid hemorrhage. **Aniracetam and Piracetam** are nootropic compounds belonging to the racetam family, believed to enhance cognitive function. This combination may be intended to improve cerebral blood flow and cognitive function, potentially for conditions involving cognitive impairment or cerebrovascular insufficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aniracetam + dihydroergocristine + nimodipine + piracetam.